BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Spinal muscular atrophy clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for spinal muscular atrophy: 45 (22 sponsors; 6 newly posted in the last 180 days, 1 stopped in the last 180 days; 4 new-entrant sponsors). Momentum score 14.4, rank 46 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 2, Phase 2 11, Phase 3 11, Phase 4 3, N/A 16.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Biogen BIIB10NA 4, P1 2, P3 401
Novartis Pharmaceuticals NVS7P4 1, P3 1, NA 4, P2 121
GeneCradle Inc3P3 1, P2 202
Novartis Gene Therapies NVS2P3 1, NA 100
Scholar Rock, Inc. SRRK2P3 1, P2 100
Biohaven Pharmaceuticals, Inc. BHVN1P3 100
Celgene1P3 100
ORIC Pharmaceuticals ORIC new entrant1P3 110
Hoffmann-La Roche4P2 1, P4 2, NA 100
Guangzhou Jiayin Biotech Ltd2EARLY_P1 1, NA 100
Alcyone Therapeutics, Inc1NA 100
Ambulanzpartner Soziotechnologie APST GmbH new entrant1NA 110
argenx ARGX1P2 100
AstraZeneca AZN1P2 100
Biocad1P2 100
Exir Gene Pharmed new entrant1EARLY_P1 110
Gemma Biotherapeutics1P2 100
Lantu Biopharma1P2 100
Lanyue Biotech (Hangzhou) Co., Ltd.1P2 100
MarsiBionics1NA 100
Nikegen Pharmaceutical (Hangzhou) Company Limited new entrant1NA 110
Synchron Medical, Inc.1NA 100

New-entrant sponsors: ORIC Pharmaceuticals, Ambulanzpartner Soziotechnologie APST GmbH, Exir Gene Pharmed, Nikegen Pharmaceutical (Hangzhou) Company Limited.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2GeneCradle IncNCT05824169 Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 PatientsSpinal Muscular Atrophyrecruiting18
2026-12-31 est.P3GeneCradle IncNCT06971094 Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - PhasSMA - Spinal Muscular Atrophyactive not recruiting50

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-02P2/P3Hoffmann-La RocheNCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)completed97
2026-11-01 est.P3Scholar Rock, Inc. SRRKNCT05626855 Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabSpinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromactive not recruiting238

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "spinal muscular atrophy"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.